Source comparison
PT-141 with Food Safety: [Peptide Administration] Comparison
The table below compares fasted-state vs fed-state PT-141 administration across key pharmacokinetic and tolerability parameters based on clinical trial data and pharmacodynamic analysis. Time to Peak Plasma (Tmax) 60–75 minutes 90–120 minutes 120–150 minutes F
This comparison does not assign a generated winner or score.
- The table below compares fasted-state vs fed-state PT-141 administration across key pharmacokinetic and tolerability parameters based on clinical trial data and pharmacodynamic analysis.
- Time to Peak Plasma (Tmax)
- 60–75 minutes
- 90–120 minutes
- 120–150 minutes
- Fasted state produces fastest onset. Critical for time-sensitive research
- Peak Concentration (Cmax)
- Baseline reference (100%)
- 15–18% reduced
- 22–31% reduced
- Fed-state reduces bioavailability by up to one-third. Unacceptable variability
- Nausea Incidence
- 18–22%
- 35–42%
- 40–48%
- Fasted dosing cuts nausea incidence in half. Primary tolerability advantage
- Duration of GI Discomfort
- 4–6 hours
- 6–8 hours
- Fed-state prolongs side effects beyond research observation window
- Plasma Half-Life (t½)
- 2.7 hours
- 2.7 hours (unchanged)
- Half-life unaffected. Only absorption kinetics change
- Bottom Line
- Optimal for reproducibility
- Acceptable only if timing cannot be controlled
- Avoid entirely in controlled research
- Fasted-state administration is the only protocol that ensures consistent pharmacokinetics and tolerability